Global Pleuromutilin Antibiotic Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pleuromutilin Antibiotic Market Research Report 2024
Pleuromutilin is a broad-spectrum diterpene antibiotic produced by Pleurotus mutilus. It is the precursor of semi-synthetic derivatives of pleuromutilin and can effectively inhibit most Gram-negative bacteria. positive bacteria and some Gram-negative bacteria.
According to Mr Accuracy reports’s new survey, global Pleuromutilin Antibiotic market is projected to reach US$ 115.7 million in 2029, increasing from US$ 97.3 million in 2022, with the CAGR of 5.0% during the period of 2024 to 2029.
Pleuromutilin’s market is driven by its effectiveness against specific bacterial infections and its widespread use in the veterinary and poultry medicine sectors. Its successful application in veterinary medicine and increasing demand have propelled market growth. Additionally, concerns about antibiotic resistance have prompted the livestock industry to adopt more sustainable veterinary medicines, with Pleuromutilin being considered a relatively low-resistance option, further boosting market demand. However, the Pleuromutilin market also faces several challenges. One of these challenges is the continuous rise in antibiotic resistance, which may limit its long-term effectiveness. Furthermore, some regions and markets may have stricter regulations on antibiotic use, posing challenges to market access for Pleuromutilin. Additionally, the veterinary sector’s interest in alternative treatment methods and greener veterinary medicines could impact the growth of the Pleuromutilin market. Therefore, the market needs to continually address challenges such as antibiotic resistance and regulatory restrictions to maintain sustainable growth.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pleuromutilin Antibiotic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Sunny Biotech
Hebei Weiyuan
Shandong Shengli
Shandong Lukang
Qingdao Dierman
Qilu Pharma
Huvepharma
Novartis
Vethellas
Elanco
Segment by Type
Premix
API Powder
Livestock
Poultry
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Pleuromutilin Antibiotic report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Pleuromutilin Antibiotic market is projected to reach US$ 115.7 million in 2029, increasing from US$ 97.3 million in 2022, with the CAGR of 5.0% during the period of 2024 to 2029.
Pleuromutilin’s market is driven by its effectiveness against specific bacterial infections and its widespread use in the veterinary and poultry medicine sectors. Its successful application in veterinary medicine and increasing demand have propelled market growth. Additionally, concerns about antibiotic resistance have prompted the livestock industry to adopt more sustainable veterinary medicines, with Pleuromutilin being considered a relatively low-resistance option, further boosting market demand. However, the Pleuromutilin market also faces several challenges. One of these challenges is the continuous rise in antibiotic resistance, which may limit its long-term effectiveness. Furthermore, some regions and markets may have stricter regulations on antibiotic use, posing challenges to market access for Pleuromutilin. Additionally, the veterinary sector’s interest in alternative treatment methods and greener veterinary medicines could impact the growth of the Pleuromutilin market. Therefore, the market needs to continually address challenges such as antibiotic resistance and regulatory restrictions to maintain sustainable growth.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pleuromutilin Antibiotic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sunny Biotech
Hebei Weiyuan
Shandong Shengli
Shandong Lukang
Qingdao Dierman
Qilu Pharma
Huvepharma
Novartis
Vethellas
Elanco
Segment by Type
Premix
API Powder
Segment by Application
Livestock
Poultry
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Pleuromutilin Antibiotic report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices